These services included testing for the BRCA1 or BRCA2 mutation in patients without cancer who met US Task Force on Preventive Services guidelines as well as genetic testing for Lynch syndrome according to National Comprehensive Cancer Network guidelines. This evidence concerns the gene BRCA2 and cancer.